FORT WASHINGTON, Pa., June 06, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that Carole Sable, M.D., has been named Chief Medical Officer, effective immediately. Dr. Sable will oversee the clinical development of Vitae’s pipeline, including wholly owned mid-stage clinical assets VTP-43742, an oral RORyt inhibitor being developed for autoimmune disorders and currently being assessed in moderate to severe psoriasis, and VTP-38543, a topical LXRβ selective agonist being studied in mild to moderate atopic dermatitis.
“We are pleased to welcome Carole to the Vitae team as our Chief Medical Officer,” said Jeff Hatfield, President and Chief Executive Officer of Vitae. “Carole has a demonstrated track record of success in leading clinical development efforts in multiple therapeutic areas, from discovery through NDA filing. This broad clinical expertise will be invaluable to Vitae as we continue advancing and expanding our pipeline of novel therapies for difficult-to-drug targets with high unmet medical need.”
Dr. Sable brings to Vitae more than 20 years of diverse clinical development and executive management experience, having been involved in all phases of clinical research, including the filing of several New Drug Applications with the U.S. Food and Drug Administration, as well as multiple Worldwide Marketing Applications. She most recently served as Chief Medical Officer of REVOLUTION Medicines, Inc. Prior to REVOLUTION Medicines, Dr. Sable served as Chief Medical Officer at SCYNEXIS, Inc. In this role, she was responsible for all clinical development, clinical pharmacology and regulatory activities. Earlier in her career, Dr. Sable has held several senior positions at Merck & Co., Inc., where she oversaw preparation of the New Drug Application for BELSORMA®, leading to its approval in 2014. Dr. Sable also served as Chief Medical Officer of Novexel SA, where she led worldwide clinical development activities until the company’s acquisition by AstraZeneca in 2010. Additionally, she has authored nearly 60 scientific reviews and articles.
“I look forward to supporting the advancement of Vitae’s potential first-in-class therapies for patients with autoimmune disorders and atopic dermatitis who are underserved by currently marketed treatments,” said Dr. Sable.
Dr. Sable earned her M.D. at Jefferson Medical College of Thomas Jefferson University and subsequently completed her internship and residency in internal medicine at the University of Virginia Hospital. She then completed a fellowship in infectious diseases at the University of Virginia Health Sciences Center.
About Vitae Pharmaceuticals
Vitae Pharmaceuticals is a clinical-stage biotechnology company developing first-in-class product candidates with potential to transform the treatment paradigm for patients with significant unmet medical needs. Initial indications being pursued include psoriasis, other autoimmune disorders, and atopic dermatitis. Vitae’s lead clinical assets include VTP-43742, an oral RORyt inhibitor currently being studied in patients with moderate to severe psoriasis, and VTP-38543, an LXRβ selective agonist being studied in patients with mild to moderate atopic dermatitis.
For additional information, please visit the company's website at www.vitaepharma.com.
Safe Harbor Statement
This release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including, but not limited to, the development of Vitae’s clinical programs. These forward-looking statements are subject to a number of risks, including the risk factors set forth from time to time in Vitae’s SEC filings, including, but not limited to, the risks that are described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Vitae’s Annual Report on Form 10-K for the year ended December 31, 2015 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, which are on file with the SEC and available on the SEC’s website at www.sec.gov.
In addition to the risks described above and in Vitae’s other filings with the SEC, other unknown or unpredictable factors also could affect Vitae’s results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Vitae undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
INVESTORS: Vitae Pharmaceuticals, Inc. Richard S. Morris, CPA Chief Financial Officer (215) 461-2000 email@example.com Westwicke Partners John Woolford (443) 213-0506 firstname.lastname@example.org MEDIA: 6 Degrees PR Tony Plohoros (908) 591-2839 email@example.com
Source:Vitae Pharmaceuticals, Inc.